Biome Australia Ltd Reports Record Quarterly and Half-Year Sales
Key points
- Q2 FY26 revenue up 40.9% on PCP and 9.1% on Q1 FY26
- H1 FY26 revenue up 40.2% on PCP
- Robust demand for clinically-proven probiotic products
Full summary
Biome Australia Limited (ASX: BIO) has provided a trading update for Q2 FY26, reporting continued strong sales growth. The company achieved sales revenue of $6.48 million for Q2 FY26, representing a 40.9% increase on the previous corresponding period (Q2 FY25: $4.6 million) and a 9.1% sequential growth on Q1 FY26. This result is particularly strong given Q2 is typically a seasonally softer period due to reduced December trading days and the pharmacy channels' focus on gifting categories during the holiday season. Half-year sales revenue reached $12.42 million, representing a 40.2% growth on the previous corresponding period (H1 FY25: $8.86 million). This performance reflects robust demand for Biome's clinically-proven probiotic products. Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. The company aims to improve health outcomes and quality of life, and make its products accessible to all.
Summary generated by a large language model. Please interpret with care.